Characterization of tirzepatide‐treated patients achieving different glycemic control levels in SURPASS‐AP‐Combo
Authors' conclusion
These findings may help to inform clinical decisions in Asia-Pacific patients with type 2 diabetes.
Study context
- Population
- Asia-Pacific patients with T2D on tirzepatide without rescue medication; 56.9% male, mean age 53.1 years, mean baseline HbA1c 8.7% (71.6 mmol/mol)
- Participants
- 598 patients
- Comparison
- Tirzepatide-treated patients achieving HbA1c <7.0% vs ≥7.0% at week 40; within <7.0%: <5.7% vs 5.7% to 6.5% vs >6.5% to <7.0%
Methodological detailssubgroup analysis
- Subgroup analysis
Primary result
As reported in the abstract
week 40
- HbA1c <7.0% vs ≥7.0%: slightly younger, shorter disease duration and lower baseline HbA1c; greater improvements in HbA1c, fasting serum glucose, body weight, BMI, waist circumference, waist-height ratio, diastolic BP, lipids and SMBG at week 40
- HbA1c <5.7% vs 5.7% to 6.5% and >6.5% to <7.0%: much younger, much lower HbA1c, further improvements in metabolic markers
- Post hoc analysis
Safety
Safety and hypoglycemia
- Tirzepatide well tolerated irrespective of HbA1c level achieved, with a low incidence of hypoglycemic events
Original publication
Characterization of tirzepatide‐treated patients achieving different glycemic control levels in SURPASS‐AP‐Combo. Obesity (Silver Spring). Published 28 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →